Independent review facility-assessed progression-free survival and overall survival were significantly better in the tiragolumab plus atezolizumab and chemotherapy group compared with chemotherapy alone for unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma. These data support the rationale for exploring dual checkpoint inhibition added to chemotherapy for this group of patients with a high unmet need.
[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology | | Chih-Hung Hsu, Zhihao Lu, Shegan Gao, Junye Wang, Jong-Mu Sun, Tianshu Liu, Qingxia Fan, Jun Cai, Feijiao Ge, Sijing Li, Li Zhang, Edward Cha, Simon Allen, Lin Shen
Topics: blood-cancer, cervical-cancer, immunotherapy, chemotherapy, clinical-trials